Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Modified Preloaded System for Renal Arteries in Fenestrated Endografting (MPSRA) (MPSRA)

4. februar 2022 oppdatert av: Enrico Gallitto, University of Bologna

Modified Preloaded System for Renal Arteries in Fenestrated Endografting

Advanced Endovascular repair of aneurysms and dissections involving thoraco-abdominal (type I-IV) and complex abdominal (juxta and para-renal) aorta is a ground-gaining procedure allowing favorable results in high surgical risk patients. The availability of iliac vessels navigation and the major role of lower leg perfusion in order to decrease the risk of spinal cord ischemia during these complex procedures, led to the development of devices with lower sheaths sizes and to the improvement of the technique with preloaded devices for visceral vessels in order to navigate in hostile anatomies or when an iliac access is not available. The aim of the study is to evaluate in a prospective single center observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries in fenestrated endografting in the routine treatment of paravisceral and thoraco-abdominal aortic pathologies.

Studieoversikt

Detaljert beskrivelse

Thoracoabdominal aortic aneurysm (TAAA) and complex abdominal aortic aneurysms (AAA) represents an evolving pathology that involves to varying degrees both the descending thoracic aorta and the abdominal aorta. These aneurysms, according to their localization and involvement in the thoracic and abdominal aorta, have been classified according to Crawford into 4 groups (I-IV) for the TAAA and in pararenal/juxtarenal (p/j-AAA) for AAA when a standard endovascular repair is not possible.

The prevalence of these pathologies is currently not well known, but high mortality rates are reported in the population carrying TAAAs and j/p-AAAs that have not undergone surgical treatment, most of which are due to aortic rupture.

Among of the main complications related to TAAA endovascular repair and to complex AAA we can account spinal cord ischemia, lower leg ischemia and logo-operative times, that all can contribute to decrease overall technical and clinical success.

A particular subgroup of TAAAs is represented by post-dissection thoracoabdominal aneurysms (PDTAA), which represents an evolving pathology and one of the main chronic complications in outcomes of acute chronic dissection. In these particular subset of patients, as well as in patient with highly calcified and hostile accesses, the risk of post-operative spinal cord ischemia is higher and the availability of both iliac access navigability is not always possible, leading to technical failure, intraoperative complications and need for adjunctive invasive procedures in high surgical risk patients.

The fenestrated and branched endoprostheses (F/B-EVAR) represent a technology that is now firmly used for the treatment of thoraco-abdominal degenerative aneurysmal pathology in superspecialized centers. Recently, the technology with F/B-EVAR has also been used in the treatment of PDTAA, IMH and PAU, showing satisfactory results. This experience has been carried out in some centers, in the absence, however, of a wider and generalized experience. All these type of endografts are custom-made devices, requiring therefore a lading time for production and delivering before being implanted into the specific patient.

In order to overcome main drawbacks of these procedures, such us long operating time due to fenestrations and vessels cannulation, to avoid bilateral lower limbs ischemia due to large bore introducer sheaths and to accomplish successful delivery even in patient without navigability of both iliac accesses, a modified preloaded system for renal arteries has been developed by Cook (Cook Medical, Bloomington, IN, USA).

The aim of the study is to evaluate in a prospective single center study observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries developed by Cook Medical with bi-port handle system in the field of fenestrated endografting during the routine treatment of thoraco-abdominal and paravisceral abdominal aortic pathologies.

Studietype

Observasjonsmessig

Registrering (Forventet)

35

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Emilia Romagna
      • Bologna, Emilia Romagna, Italia, 40138
        • Rekruttering
        • University of Bologna
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All elective patients treated in a single center institution, with the standard of care for thoraco-abdominal and para-juxta-renal abdominal aortic aneurysms using fenestrated/branched custom-made endograft developed by Cook Medical with modified preloaded system for renal arteries.

Beskrivelse

Inclusion Criteria:

  • Diagnosis of thoraco-abdominal or complex abdominal aortic aneurysm confirmed by a Computed tomography Angiography (CTA).
  • Etiologies will be degenerative aneurysms, inflammatory aneurysms, chronic post-dissectional aneurysms, penetrating aortic ulcers, failure of prior surgical or endovascular repair.
  • Elective aneurysmal repair of patient with maximum diameter greater than 55 mm, or fast growing, or symptomatic aneurysms.
  • Endovascular repair performed using custom-made fenestrated and/or branched endografting with presence of modified preloaded system with modified handle and preloaded catheters for visceral vessels cannulation.

Exclusion Criteria:

  • Patients submitted to advanced fenestrated and branched endovascular repair with other grafts besides the Cook Medical custom-made endograft or without modified handle preloaded delivery system.
  • Physician-modified devices
  • Patient treated with hybrid and/or open technique as well as parallel grafts (such as chimney/snorkel/periscope)
  • Patient treated as emergent/urgent patients or aneurysmal rupture
  • Patient who can not wait for the lead time required for endograft production and delivery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Technical Success
Tidsramme: Intra-operative final completion angiography.
Successful deployment of custom-made modified endograft, target vessel patency and aneurysm exclusion, in absence of intra-operative mortality.
Intra-operative final completion angiography.
Mortality
Tidsramme: Within the first 30-days from the procedure.
Assessment of mortality related to procedure
Within the first 30-days from the procedure.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cardiovascular Adverse Events
Tidsramme: Within the first 30-days from the procedure.
Cardiopulmonary and renal events related to the procedure.
Within the first 30-days from the procedure.
Neurologic Adverse Events
Tidsramme: Within the first 30-days from the procedure.
Incidence of Spinal Cord Ischemia (transient/permanent) and Stroke
Within the first 30-days from the procedure.
Vessel Instability
Tidsramme: Within the first 30-days from the procedure.
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
Within the first 30-days from the procedure.
Rate of early reintervention
Tidsramme: Within the first 30-days from the procedure.
Any re-intervention needed after the type of procedure and the specific reason
Within the first 30-days from the procedure.
Overall Survival
Tidsramme: Through study completion, an average of 1 year.
Assessment of mortality in the post-operative period
Through study completion, an average of 1 year.
Aorta Related Survival
Tidsramme: Through study completion, an average of 1 year.
Assessment of mortality in the post-operative period related to aortic procedure or aortic related death.
Through study completion, an average of 1 year.
Freedom from reintervention
Tidsramme: Through study completion, an average of 1 year.
Time from procedure to the first aortic related/procedure related reintervention
Through study completion, an average of 1 year.
Freedom from Vessel Instability
Tidsramme: Through study completion, an average of 1 year.
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
Through study completion, an average of 1 year.
Freedom from Major Endoleaks
Tidsramme: Through study completion, an average of 1 year.
Time from procedure to the presence of high-flow endoleak (TypeI/III) and from endoleak that required reintervention
Through study completion, an average of 1 year.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2019

Primær fullføring (Forventet)

1. juni 2022

Studiet fullført (Forventet)

1. desember 2022

Datoer for studieregistrering

Først innsendt

4. januar 2022

Først innsendt som oppfylte QC-kriteriene

24. januar 2022

Først lagt ut (Faktiske)

4. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. februar 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. februar 2022

Sist bekreftet

1. februar 2022

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Juxtarenal aortaaneurisme

3
Abonnere